## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.1% in mid entry zone (3.0-6.0%), top 3% cross-sectional ranking. Short-term MRS_5 (2.0%) confirms momentum alignment. Outperforming sector by 5.1%. Caution: overbought RSI (79).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($43.34)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. The Bull Case For Omnicell (OMCL) Could Change Following Titan XT AI Medication Platform Launch**
- Source: Simply Wall Street | 20251218T060930 | Bullish | Relevance: 100%
- Omnicell recently launched Titan XT, an AI-enabled automated dispensing system, which is expected to reinforce the company's investment narrative focused on automation, cloud-based medication management, and recurring revenue growth. This new platform, coupled with raised 2025 revenue guidance, highlights Omnicell's reliance on its OmniSphere platform for growth. While it strengthens the thesis, the long-term impact will depend on broader OmniSphere adoption and how well Omnicell navigates competitive and regulatory landscapes.

**2. Texas Permanent School Fund Corp Decreases Stock Position in Omnicell, Inc. $OMCL**
- Source: MarketBeat | 20251218T104530 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp reduced its stake in Omnicell, Inc. by 15.1% in the second quarter, now holding 165,729 shares valued at $4.87 million. Despite this, other institutions like Sumitomo Mitsui and Intech increased their positions, with institutional investors collectively owning 97.70% of the stock. Omnicell currently trades near its 52-week high with a market cap of $2.06 billion, and analysts have a "Hold" consensus rating with an average target price of $43.00.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Benchmark | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Benchmark | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 10 ($2.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 25.4x stretched relative to 8% growth. Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 25.4 |
| Current P/E | 27.4 |
| YoY Growth | 7.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at 5.1% (minimal 5-day change). Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 97th percentile. MRS_5 at 2.0% confirms short-term momentum alignment. Outperforming sector by 5.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 79, risk of mean reversion. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.06% (CS: 97) | Strong |
| RSI_14 | 79.2 | Overbought |
| MACD Histogram | 0.38 | Bullish |
| vs SMA20 | 1.139x | Above |
| vs SMA50 | 1.296x | Above |
| vs SMA200 | 1.457x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $46.84
- **Stop Loss:** $43.34 (7.5% risk)
- **Target:** $52.09 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 342
- **Position Value:** $16,019.28
- **Portfolio %:** 16.02%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*